Contributions to the treatment of primary liver cancer. 4′-Epidoxorubicin and cisplatin studied in hepatocarcinoma cell cultures and in partially hepatectomized rats

References

• Kew M C. The development of hepatocellular cancer in humans. Cancer Surv 1986; 5: 719–39
   Google Scholar
• The Cancer Registry of Norway. The Cancer Registry of Norway. The incidence of cancer in Norway. 1982-1986
   Google Scholar
• Craig J R, Peters R L, Edmondson H A, Omata M. Fibrolamellar carcinoma of the liver. Cancer 1980; 46: 372–9
   PubMed Web of Science ®Google Scholar
• Reaman G H, Cohen L F. Less frequently encountered malignant neoplasms in the young. Cancer in the young, A S Levine. Masson Publishing USA, Inc., New York 1982; 710–1
   Google Scholar
• Hafstrøm L. Liver cancer–present status. Act Chir Sc 1988, suppl 541: 57–62
   Google Scholar
• Hall K S, Endresen L, Huitfeldt H S, Rugstad H E. Induction of in vitro resistance to 4′-epidoxorubicin and cisdichlorodiammineplatinum in hepatoma cells. Anticancer Res 1991; 11: 817–24
   PubMed Web of Science ®Google Scholar
• Hall K S, Endresen L, Rugstad H E. Verapamil potentiates 4′-epidoxorubicin cytotoxicity in a rat hepatoma cell line and in a substrain resistant to 4′-epidoxorubicin. Pharmacol Toxicol 1990; 67: 402–5
   Google Scholar
• Hall K S, Lien B, Paulsen J E, Clausen O PF, Bergan A, Rugstad H E. Effect of preoperative 4′-epidoxorubicin (Epi-Adriamycin) treatment on the regeneration and function of the liver in partially hepatectomized rats. Eur Surg Res 1989; 21: 196–204
   Google Scholar
• Hall K S, Lien B, Morkrid L, Clausen O PF, Bergan A, Rugstad H E. Long-term toxicity of preoperative 4′-epidoxorubicin (Epi-Adriamycin) in partially hepatectomized rats. Eur Surg Res 1991; 23: 114–22
   Google Scholar
• Hall K S, Endresen L, Schjerven L, Rugstad H E. The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4′-epidoxorubicin in rats. Cancer Chemother Pharmacol 1990; 26: 444–8
   Google Scholar
• Hall K S, Lien B, Endresen L, Bergan A, Rugstad H E. Changes in pharmacokinetics of cisplatin after hepatic resection in rats. Drug Met Disp 1991; 19: 725–8
   Google Scholar
• Hochster H S, Green M D, Speyer J, Fazzini E, Blum R, Muggia F M. 4′-Epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma. J Clin Oncol 1985; 3: 1535–40
   PubMed Web of Science ®Google Scholar
• Pierro A, Langevin A M, Filler R M, Liu P, Phillips M J, Greenberg M L. Preoperative chemotherapy in ‘unresectable’ hepatoblastoma. J Pediatr Surg 1989; 24: 24–9
   PubMedGoogle Scholar
• Quinn J J, Altman A J, Robinson H T, Cooke R W, Hight D W, Foster J H. Adriamycin and cisplatin for hepatoblastoma. Cancer 1985; 56: 1926–9
   PubMedGoogle Scholar
• Mouridsen H T, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksborg S, Hellsten S, Kjaer M, Peterson C, Skovsgard T, S0rensen J B, Trope C, Aabo K. Current status of epirubicin (Farmoru-bicin) in the treatment of solid tumours. Acta Oncol 1990; 29: 257–85
   PubMed Web of Science ®Google Scholar
• Fojo A, Akiyama S, Gottesman M M, Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985; 45: 3002–7
   PubMed Web of Science ®Google Scholar
• Willingham M C, Richert N D, Cornwell M M, Tsuruo T, Hamada H, Gottesman M M, Pastan I H. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987; 35: 1451–6
   PubMed Web of Science ®Google Scholar
• Roninson I B, Chin J E, Choi K, Gros P, Housman D E, Fojo A, Shen D W, Gottesman M M, Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 4538–42
   PubMed Web of Science ®Google Scholar
• Ford J M, Hait W N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155–99
   PubMed Web of Science ®Google Scholar
• Cornwell M M, Pastan I, Gottesman M M. Certain calcium channel blockers bind specially to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glucoprotein. J Biol Chem 1987; 262: 2166–70
   PubMed Web of Science ®Google Scholar
• Bessho F, Kinumaki H, Kobayashi M, Habu H, Nakamura K, Yokota S, Tsuruo T, Kobayashi N. Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltia-zem. Med Pediatr Oncol 1985; 13: 199–202
   PubMedGoogle Scholar
• Durie B GM, Dalton W S. Reversal av drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68: 203–6
   PubMed Web of Science ®Google Scholar
• Cairo M S, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989; 49: 1063–6
   PubMed Web of Science ®Google Scholar
• Demicheli R, Jirillo A, Bonciarelli G, Lonardi F, Balli M, Bandello A. 4′-Epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori 1989; 75: 245–7
   PubMed Web of Science ®Google Scholar
• Miller T P, Grogan T M, Dalton W S, Spier C M, Scheper R J, Salmon S E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17–24
   PubMed Web of Science ®Google Scholar
• Rugstad H E. Metallothionein-a unique protein with multiple detoxifying properties?. Eur Surg Res 1984; 16(suppl 2)102–12
   Google Scholar
• Bakka A, Endresen L, Johnsen A BS, Edminson P D, Rugstad H E. Resistance against cis-dichloro-diammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 1981; 61: 215–26
   PubMed Web of Science ®Google Scholar
• Endresen L, Schjerven L, Rugstad H E. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cisdichlorodiammineplatinum. Acta Pharmacol et toxicol 1984; 55: 183–7
   PubMedGoogle Scholar
• Kelley S L, Basu A, Teicher B A, Hacker M P, Ha-Mer D H, Lazo J S. Overexpression of metallothio-nein confers resistance to anticancer drugs. Science 1988; 241: 1813–5
   PubMed Web of Science ®Google Scholar
• Farnworth P G, Hillcoat B L, Roos I AG. Metal-lothionein induction in mouse tissues by cis-dichlorodiammineplatinum(II) and its hydrolysis prod43ucts. Chem Biol Interact 1989; 69: 319–32
   PubMed Web of Science ®Google Scholar
• Hill B T. Implications of certain kinetic and biological parameters for preoperative chemotherapy. Recent Results Cancer Res 1986; vol 103: 41–53
   Google Scholar
• Grosfeld J L, Weber T R, Baehner R L. Comparative toxicity of chemotherapy following partial hepa-tectomy. J Pediatr Surg 1981; 16: 950–4
   Google Scholar
• Tanaka Y, Nagasue N, Kanashima R, Inokuchi K, Shirota A. Effect of doxubicin on liver regeneration and host survival after two-thirds hepatectomy in rats. Cancer 1982; 49: 19–24
   Google Scholar
• Nagasue N, Kobayashi M, Iwaki A, Yukaya H, Kanashima R, Inokughi K. Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat. Cancer 1978; 41: 435–43
   Google Scholar
• Kohno H, Inokuchi K. Effects of postoperative adjuvant chemotherapy on liver regeneration in partially hepatectomized rats. Jap J Surg 1984; 14: 515–23
   Google Scholar
• Hoyle R M, Banes A, Bernard S, Thomas C G. Effects of 2′-deoxy-5-fluorouridine on regenerating liver following partial hepatectomy in the rat. J Surg Res 1988; 45: 181–6
   Google Scholar
• Post J, Huang C Y, Hoffman J. The replication time and pattern of the liver cell in the growing rat. J Cell Biol 1963; 18: 1–12
   PubMedGoogle Scholar
• Stöcker E. Der Proliferationsmodus in Niere und Leber. Tagung der Deutsche Gesellschaft fur Pato-logie. 1966; 50: 53–74
   Google Scholar
• Bucher N LR. Regeneration of mammalian liver. Int Rev Cytol 1963; 15: 245–300
   PubMed Web of Science ®Google Scholar
• Vajrabukka T, Bloom A L, Sussman M, Wood C B, Blumgart L H. Postoperative problems and management after hepatic resection for blunt injury to the liver. Br J Surg 1975; 62: 189–200
   Google Scholar
• Selden C, Johnstone R, Darby H, Gupta S, Hodgson H JF. Human serum does contain a high molecular weight hepatocyte growth factor: studies pre- and post-hepatic resection. Biochem Biophys Res Commun 1986; 139: 361–6
   PubMedGoogle Scholar
• Lin T Y, Lee C S, Chen C C, Liau K Y, Lin W SJ. Regeneration of human liver after hepatic lobectomy studied by repeated liver scanning and repeated needle biospy. Ann surg 1979; 190: 48–53
   PubMed Web of Science ®Google Scholar
• Nagasue N, Yukaya H, Ogawa Y, Kohno H, Nakamura T. Human liver regeneration after major hepatic resection. Ann Surg 1987; 206: 30–9
   PubMed Web of Science ®Google Scholar
• Enge I. Pre- and postoperative angiography in primary hepatic tumors. In: Angiography in regeneration of the liver. An experimental and clinical study. Thesis. Oslo 1977; 85–141
   Google Scholar
• Bertazzoli C, Rovero C, Ballenni L, Lux B, Balconi F, Antongiovanni V, Magrini U. Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985; 79: 412–22
   PubMed Web of Science ®Google Scholar
• Cersosimo R J, Hong W K. Epirubicin: A review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425–39
   PubMed Web of Science ®Google Scholar
• Isner J M, Ferrans V J, Cohen S R, Witkind B G, Vir-Mani R, Gottdiener J S, Beck J R, Roberts W S. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Am J Cardiol 1983; 51: 1167–74
   PubMed Web of Science ®Google Scholar
• Kantrowitz N E, Bristow M R. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195–200
   PubMed Web of Science ®Google Scholar
• Weenen H, Lankelma J, Penders P GM, McVie J G, Huinink W W, De Planque M M, Pinedo H M. Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1983; 1: 59–64
   Google Scholar
• Mross K, Maessen P, Van der Vijgh W JF, Gall H, Boven E, Pinedo H M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517–26
   PubMed Web of Science ®Google Scholar
• Eksborg S. Pharmacokinetics of anthracyclines. Acta Oncol 1989; 28: 873–6
   PubMed Web of Science ®Google Scholar
• Maessen P A, Mross K B, Pinedo H M, Van der Vijgh W JF. Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer Chemother Pharmacol 1987; 20: 85–7
   PubMedGoogle Scholar
• DeSimone P A, Yancey R S, Coupal J J, Butts J D, Hoeschel J D. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cisdichlorodiammineplatinum(II). Cancer Treat Rep 1979; 63: 951–60
   PubMedGoogle Scholar
• Litterst C L, LeRoy A F, Guarino A M. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplati-num(II) to animals. Cancer Treat Rep 1979; 63: 1485–92
   PubMedGoogle Scholar
• Siddik Z H, Newell D R, Boxall F E, Harrap K R. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987; 36: 1925–32
   PubMed Web of Science ®Google Scholar
• Mistry P, Lee C, McBrien D CH. Intracellular metabolites of cisplatin in the rat kidney. Cancer Chemother Pharmacol 1989; 24: 73–9
   PubMed Web of Science ®Google Scholar
• Bridges J W, Chasseaud L F, Cohen G M, Walker C H. Application of phrmacokinetics. Animals and alternatives in toxicity testing, M Balls, R J Riddel, A N Worden. Academic Press, London 1983; 30–67
   Google Scholar
• Donelli M G, D'Incalci M, Garattini S. Pharmacokinetic studies of anticancer drugs in tumor-bearing animals. Cancer Treat Rep 1984; 68: 381–400
   PubMedGoogle Scholar
• Frei I II. Clinical cancer research: An embattled species. Cancer 1982; 50: 1979–92
   PubMed Web of Science ®Google Scholar
• Bengmark S, Hafstrom L, Jeppsson B, Sundqvist K. Primary carcinoma of the liver: Improvement in sight? World J Surg 1982; 6: 54–60
   Google Scholar
• Sakurai M, Okamura J, Kuroda C. Transcatheter chemoembolization effective for treating hepatocellular carcinoma. A histopathologic study. Cancer 1984; 54: 387–92
   PubMed Web of Science ®Google Scholar
• Nakamura H, Tanaka T, Hori S, Yoshioka H, Kuroda C, Okamura J, Sakurai M. Transcatheter embolization of hepatocellular carcinoma: Assessmerit of efficacy in cases of resection following embolization. Radiology 1983; 147: 401–5
   PubMed Web of Science ®Google Scholar
• Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J, Ishiguro S, Ohigashi H, Ishikawa O, Fukuda I, Furukawa H, Koyama H, Iwanaga T. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23: 126–8
   Google Scholar
• Holton C P, Burrington J D, Hatch E I. A multiple chemotherapeutic approach to the management of hepatoblastoma. Cancer 1975; 35: 1083–7
   PubMed Web of Science ®Google Scholar
• Weinblatt M E, Siegel S E, Siegel M M, Stanley P, Weitzman J J. Preoperative chemotherapy for unresectable primary hepatic malignancies in children. Cancer 1982; 50: 1061–4
   PubMedGoogle Scholar
• Mahour G H, Wogu G U, Siegel S E, Isaacs H. Improved survival in infants and children with primary malignant liver tumors. Am J Surg 1983; 146: 236–240
   PubMed Web of Science ®Google Scholar
• Kitagawa T. Responsiveness of hyperplastic lesions and hepatomas to partial hepatectomy. Gann 1971; 62: 217–24
   Google Scholar
• Seglen P O, Saeter G, Schwarze P E. Liver tumor promoters stimulate growth of transplanted hepatocellular carcinomas. Hepatology 1990; 12: 295–300
   Google Scholar
• Fisher B, Gunduz N, Saffer E A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43: 1488–92
   PubMed Web of Science ®Google Scholar
• Fichtner I, Tanneberger S. Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use. Anticancer Res 1987; 7: 227–34
   Google Scholar
• Long L, Jonasson O, Roberts S, McGrath R, McGrew E A, Cole W H. Cancer cells in blood. Arch Surg 1960; 80: 910–9
   PubMed Web of Science ®Google Scholar
• Roberts S, Jonasson O, Long L, McGrew E A, McGrath R, Cole W H. Relationship of cancer cells in the circulating blood to operation. Cancer 1962; 15: 232–40
   Google Scholar
• Salsbury A J. The significance of the circulating cancer cell. Cancer Treat Rev 1975; 2: 55–72
   PubMedGoogle Scholar
• Goldstein L J, Galski H, Fojo A, Willingham M, Lai S L, Gazdar A, Pirker R, Green A, Crist W, Brodeur G M, Lieber M, Cossmann J, Gottesman M M, Pastan I. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–24
   PubMed Web of Science ®Google Scholar
• Thorgeirsson S S, Huber B E, Sorrell S, Fojo A, Pastan I, Gottesman M M. Expression of the multi-drug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987; 236: 1120–2
   PubMed Web of Science ®Google Scholar
• Benson A B, Trump D L, Koeller J M, Egorin M I, Olman E A, Witte R S, Davis T E, Tormey D C. Phase I Study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 1985; 69: 795–9
   PubMedGoogle Scholar
• Hamann S R, Todd G D, McAllister R G. The pharmacology of verapamil V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology 1983; 27: 1–8
   PubMedGoogle Scholar
• Merry S., Kerr D, Flanigan P, Milroy R, Freshney R I, Kaye S B. Multidrug resistance and anthracy-clines. Br J Cancer 1987; 56: 185, abstract
   Web of Science ®Google Scholar
• Fine R L, Koizumi S, Curt G A, Chabner B A. Verapamil (VP) does not enhance anticancer drug toxicity for human marrow myeloid-macrophage colony-forming units (CFU-GM). Proc Ann Meet Am Soc Clin Oncol 1984; 3: 154, abstract
   Google Scholar
• Yalowich J C, Zucali J R, Gross M A, Ross W E. Effects of verapamil on etopside, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res 1985; 45: 4921–4
   PubMed Web of Science ®Google Scholar
• Ozols R F, Cunnion R E, Klecker R W, Hamilton T C, Ostchega Y, Parrillo J E, Young R C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641–7
   PubMed Web of Science ®Google Scholar
• Mross K, Langenbuch T, Burk K, Hossfeld D K. Pilot phase II-study of high-dose epirubicin+ high-dose verapamil in metastatic breast cancer patients: toxicity, response rate and pharmacokinetics. Sixth NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, March, 1989
   Google Scholar
• Kerr D J, Graham J, Cummings J, Morrison J, Thompson G G, Brodie M J, Kaye S B. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986; 18: 239–42
   PubMed Web of Science ®Google Scholar